Detalles de la búsqueda
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697155
2.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086745
3.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Oncologist
; 29(4): 303-310, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995313
4.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31826360
5.
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Future Oncol
; 19(24): 1695-1708, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37605877
6.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Lancet Oncol
; 23(12): 1571-1582, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36370716
7.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Breast Cancer Res Treat
; 193(1): 95-103, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35212906
8.
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
J Transl Med
; 20(1): 290, 2022 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35761360
9.
Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement.
Support Care Cancer
; 30(12): 9877-9888, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36334157
10.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357420
11.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 189(3): 689-699, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34414532
12.
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
J Transl Med
; 19(1): 132, 2021 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33789686
13.
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Cardiovasc Diabetol
; 20(1): 150, 2021 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301253
14.
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol
; 21(10): 1283-1295, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33002436
15.
Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy.
J Cell Physiol
; 235(6): 5353-5362, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31957873
16.
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
Breast Cancer Res Treat
; 182(2): 401-409, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32500397
17.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
BMC Cancer
; 20(1): 232, 2020 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32188417
18.
Targeting Autophagy in Breast Cancer.
Int J Mol Sci
; 21(21)2020 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33105796
19.
NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells.
Int J Mol Sci
; 21(20)2020 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33096896
20.
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Int J Mol Sci
; 21(18)2020 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32899866